Navigation Links
Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
Date:11/28/2008

AMSTERDAM, Nov. 28 /PRNewswire/ -- Oncology focused biopharmaceutical company Kiadis Pharma announces today that Andrea Velardi, M.D., Professor of Clinical Immunology at the University of Perugia, Italy and Kiadis Pharma are continuing their collaboration on ATIR(TM), a product in clinical development for enabling the use of a mismatched donor in a bone marrow transplantation by preventing acute Graft versus Host Disease (GvHD) for end stage leukemia patients. Under the agreement Professor Velardi will continue the development on the selective depletion of allo-reactive T cells from mismatched donors using Kiadis Pharma's ATIR(TM). Kiadis Pharma is preparing for a multi-center pivotal study on ATIR(TM) to start early 2009 and Professor Velardi will participate in this upcoming study.

"We are very pleased with our continued collaboration with the University of Perugia and Professor Velardi, who is a leader in the field of mismatched bone marrow transplantations," says Dr. Manja Bouman, CEO of Kiadis Pharma. "This collaboration is an important milestone in the development of ATIR(TM) as a revolutionary approach to provide safe and potentially life-saving mismatched bone marrow transplantations as a treatment option for end-stage leukemia patients."

Professor Andrea Velardi says: "So far, we have treated 25 blood cancer patients who have received bone marrow from mismatched donors, including donor immune cells that are selectively depleted of cells causing acute Graft versus Host Disease using the ATIR(TM) process. The results so far are promising and I am therefore very pleased to continue to work with Kiadis Pharma in this field."

For the complete press release please go to: www.kiadis.com/news

About Kiadis Pharma

Kiadis Pharma is an oncology focused pharmaceutical development company with three products in different p
'/>"/>

SOURCE Kiadis Pharma
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
2. Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA
3. EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation
4. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
5. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 24, 2013 ... angefertigt – Bei der englischen ... , 91 % der Teilnehmer einer groß angelegten ... 20 % laut GINA [*] -Definition [1] als ... Menschen mit Asthma generell einer von vier Denkweisen zugeordnet ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Can economic ... from work motivate members of the public to increase ... including Johns Hopkins Carey Business School Assistant ... yes. Pointing to a large body of recent research ... the May 24, 2013, issue of Science that the ...
(Date:5/23/2013)... May 23, 2013  Rahal Letterman Lanigan Racing (RLL) ... blood stem cell banking and therapeutics, announced today that ... 16 Acorn Stairlifts Indy car driven by ... of the IZOD IndyCar 2013 season.   ... to support awareness of umbilical cord blood banking and ...
(Date:5/23/2013)... , May 23, 2013  Saddleback Memorial Medical Center ... became the first hospital on the West Coast to ... new surgical option provides women with a state-of-the-art, minimally ... Marc Winter , M.D., a highly regarded ... and medical director of minimally invasive surgery at Saddleback ...
Breaking Biology Technology:Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 3Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 4Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 6Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 7Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3
... CALGARY , June 1 /PRNewswire-FirstCall/ - Oncolytics ... that it has received approval from the Belgian Federal ... its Phase 3 trial examining REOLYSIN in combination with ... neck cancers. This is the same trial that was ...
... development that could lead to novel carbon composites and ... Institute of Technology today unveiled a new method for ... graphene. The research is available online in the ... graphene sheets make graphite, which has been commonly used ...
... SHENZHEN, China , May 28 /PRNewswire-Asia-FirstCall/ -- Huiheng Medical,Inc. (OTC ... China , will host a conference call,discussing its financial results for the period ended ... , , , ... , , ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 2Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 3Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 4Liquid method: pure graphene production 2Huiheng Medical, Inc. Announces Conference Call to Discuss First Quarter 2010 Results 2
(Date:5/23/2013)... said to be the world,s most popular fruit, can ... research with purple GM varieties. , "Working with ... by the addition of a specific compound, allows us ... said Professor Cathie Martin from the John Innes Centre. ... with better flavour, health and shelf life characteristics because ...
(Date:5/23/2013)... tight wrapping of genomic DNA around nucleosomes in ... expression. A team of Ludwig-Maximilians-Universitaet (LMU) in Munich ... to be locally displaced from nucleosomes for transcription. ... stored in the cell nucleus, wrapped around disk-shaped ... of four different histone proteins and accommodating two ...
(Date:5/23/2013)... history museums of the world are billions of animal ... flowers, mushrooms and grasses, all stacked, stored and preserved ... diverse collections could be critical to understanding how the ... growing human footprint if only the information were ... life with the help of a team from the ...
Breaking Biology News(10 mins):The world's favorite fruit only better-tasting and longer-lasting 2Biochemistry: Unspooling DNA from nucleosomal disks 2CU-Boulder helps tap crowds to digitize museum records of bugs and plants 2CU-Boulder helps tap crowds to digitize museum records of bugs and plants 3CU-Boulder helps tap crowds to digitize museum records of bugs and plants 4
... commercial licensing are raised by a senior doctor in this ... drug for multiple sclerosis, and its recall three months later, ... being treated. , Natalizumab was licensed by the US Food ... sclerosis on the basis of short term results from two ...
... chip ever to be developed for detecting SCID (primary ... the first time at the New York Academy of ... Past, Present, Future. The meeting will take place ... York Avenue, NY, from 8 a.m. to 5:30 p.m. ...
... Editor: Yeah, I hate it too when there's no picture ... picture of a molecule that plays a key role in ... been obtained by researchers at the European Molecular Biology Laboratory ... associated with the Université Joseph Fourier and the CNRS, in ...
Cached Biology News:First SCID gene chip to be introduced at Academy meeting on immunodeficiencies 2First SCID gene chip to be introduced at Academy meeting on immunodeficiencies 3Waking a sleeping virus 2
Economical and manually filled LN2 vacuum insulated storage container offers high capacity and low nitrogen consumption while offering convenient storage of samples....
... digitonin and digoxin. Physical form: Lyophilized powder containing ... 0.06% NaCl Preparation Note: Sodium iodide extracted fraction ... 19, 755 (1965). Unit Definition: One unit ... ATP per min at pH 7.4 at 37 ...
... the highly potent TURBO DNase (patent pending) in ... set in DNA removal capabilities. TURBO DNase is ... is much more efficient than wild type DNase ... DNA. TURBO DNase binds DNA substrates 6-fold more ...
... progressive centrifuge design and manufacturing, Thermo IEC ... Centra-CL3R (refrigerated) general purpose models provide new ... Over Sample Preparation , The CL3 series ... protocols and has speed and accuracies to ...
Biology Products: